CareMax Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

CareMax wird ein Gewinn- und Umsatzwachstum von 77.2% bzw. 26% pro Jahr prognostiziert, während der Gewinn pro Aktie um 101.9% pro Jahr wachsen soll.

Wichtige Informationen

77.2%

Wachstumsrate der Gewinne

101.9%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	20.9%
Wachstumsrate der Einnahmen	26.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Aug 14

Recent updates

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Aug 14

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Jun 20

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

May 13

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Mar 11

CareMax: Numbers Are Strong, Compelling Value On Offer

Sep 16

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

Aug 09

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

Jul 02

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CMAX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,383	-72	N/A	N/A	1
12/31/2025	1,240	-151	N/A	N/A	1
12/31/2024	772	-130	N/A	N/A	1
6/30/2024	785	-783	-62	-52	N/A
3/31/2024	810	-645	-61	-49	N/A
12/31/2023	751	-683	-62	-47	N/A
9/30/2023	764	-207	-101	-91	N/A
6/30/2023	719	-126	-94	-84	N/A
3/31/2023	667	-103	-86	-78	N/A
12/31/2022	631	-38	-76	-68	N/A
9/30/2022	585	-52	-61	-55	N/A
6/30/2022	532	-44	-54	-48	N/A
3/31/2022	405	-25	-43	-39	N/A
12/31/2021	296	-7	-28	-24	N/A
9/30/2021	206	-2	-13	-9	N/A
6/30/2021	125	12	-4	-2	N/A
3/31/2021	106	6	5	7	N/A
12/31/2020	103	8	3	5	N/A
9/30/2020	101	7	5	8	N/A
12/31/2019	91	6	6	7	N/A
12/31/2018	72	3	0	1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CMAX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CMAX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CMAX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CMAXDie Einnahmen des Unternehmens (26% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: CMAXDie Einnahmen des Unternehmens (26% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CMAX in 3 Jahren voraussichtlich hoch sein wird

CareMax Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 125%, revenue upgraded

Consensus EPS estimates upgraded to US$20.83 loss, revenue downgraded

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Consensus EPS estimates upgraded to US$33.26 loss

Price target decreased by 42% to US$26.00

Price target decreased by 17% to US$37.33

Recent updates

CareMax, Inc.(NasdaqGS:CMAX) dropped from S&P TMI Index

Interim DIP Financing Approved for CareMax, Inc.

Interim DIP Financing Approved for CareMax, Inc.

CareMax, Inc. Filed for Bankruptcy

CareMax, Inc. announced delayed 10-Q filing

Consensus EPS estimates fall by 125%, revenue upgraded

High number of new directors

CareMax Receives Non-Compliance Notice from Nasdaq Regarding Minimum MVPHS Requirement

Consensus EPS estimates upgraded to US$20.83 loss, revenue downgraded

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$33.26 loss

New major risk - Financial position

High number of new directors

CareMax, Inc. announced delayed annual 10-K filing

Price target decreased by 42% to US$26.00

Price target decreased by 17% to US$37.33

CareMax Announces 1-for-30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

CareMax Receives Non-Compliance Notice From Nasdaq

New major risk - Share price stability

New minor risk - Market cap size

Consensus EPS estimates fall by 64%

Price target increased by 9.1% to US$6.00

Consensus EPS estimates fall by 105%

New minor risk - Profitability

Caremax, Inc. Reports Unaudited Goodwill Impairment for the Three Months Ended September 30, 2023

CareMax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

CareMax, Inc. Announces Resignation of David J. Shulkin as A Member of the Board of Director

Consensus EPS estimates fall by 18%, revenue upgraded

Price target decreased by 11% to US$6.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Revenue Guidance for the Full Year of 2023

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Consensus EPS estimates upgraded to US$0.28 loss, revenue downgraded

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

Caremax, Inc. Reaffirms Full Year 2023 Guidance

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$0.42 loss

Consensus EPS estimates upgraded to US$0.49 loss, revenue downgraded

Consensus revenue estimates fall by 12%

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.50

CareMax, Inc. Appoints Ralph De La Torre as Director

Consensus forecasts updated

High number of new and inexperienced directors

CareMax, Inc. (NasdaqGS:CMAX) completed the acquisition of Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC.

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Earnings Guidance for the Full Year 2022

CareMax, Inc. Approves Appointment of Ryan O'quinn as Board of Director

CareMax, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CareMax, Inc., Annual General Meeting, Nov 02, 2022

CareMax: Numbers Are Strong, Compelling Value On Offer

Price target decreased to US$11.10

Consensus estimates of losses per share improve by 14%

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CareMax, Inc. Revises Earnings Guidance for the Full Year 2022

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

CareMax, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$11.00

High number of new and inexperienced directors

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

CareMax, Inc. (NasdaqGS:CMAX) entered into an agreement to acquire Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC for approximately $135 million.

Consensus forecasts updated

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite